PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Euroimmun Medizinische Labordiagnostika Ag

USPTO PatentsView assignee record — 71 granted patents across 28 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).

Explore the portfolio See the ranking
71
Total patents granted
28
CPC technology areas
10.9
Avg claims per patent
+307%
5-year filing velocity

The verdict

Euroimmun holds 71 US patents across 28 technology areas — rank #4,876 of 50,000 tracked assignees.

#4,876
of 50,000 US assignees by volume
Top 24%
by Innovation Score (45.1/100)
10.9
avg claims per patent
+307%
filing velocity, last 5 yrs

Portfolio overview

EUROIMMUN Medizinische Labordiagnostika AG has been granted 71 US utility patents between 2016 and 2025, placing EUROIMMUN Medizinische Labordiagnostika AG at rank #4,876 across all assignees tracked by PlainPatent. This portfolio spans 28 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.9 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a Foreign Corporation, EUROIMMUN Medizinische Labordiagnostika AG is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 45.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 57 grants, compared with 14 in the 2015–2019 window — a +307% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. EUROIMMUN Medizinische Labordiagnostika AG's 10.9 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while a multi-domain presence across 28 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark EUROIMMUN Medizinische Labordiagnostika AG against peers pursuing similar technology classes.

How does EUROIMMUN compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows EUROIMMUN holds 71 patents — placing it at rank #4,876 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

EUROIMMUN's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

05101520 201620182019202020212022202320242025 8
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
EUROIMMUN Medizinische Labordiagnostika AG patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 1 1.4%
2018 9 12.7%
2019 4 5.6%
2020 16 22.5%
2021 10 14.1%
2022 9 12.7%
2023 8 11.3%
2024 6 8.5%
2025 8 11.3%

Which technologies does EUROIMMUN Medizinische Labordiagnostika AG patent most?

Top 15 of 28 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Multi-domain
Claim Depth Simple
Velocity Accelerating

Where it ranks

Overall rank by patents

#4,876

Across all tracked assignees

Innovation Score

45.1 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does EUROIMMUN Medizinische Labordiagnostika AG hold?
EUROIMMUN Medizinische Labordiagnostika AG holds 71 US granted patents filed between 2016 and 2025, spanning 28 technology areas.
What is EUROIMMUN Medizinische Labordiagnostika AG's Innovation Score?
EUROIMMUN Medizinische Labordiagnostika AG has an Innovation Score of 45.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does EUROIMMUN Medizinische Labordiagnostika AG focus on?
EUROIMMUN Medizinische Labordiagnostika AG's top technology area is G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES) with 46 patents. The company has filed patents in 28 CPC subclasses total.
Is EUROIMMUN Medizinische Labordiagnostika AG's patent filing rate increasing or decreasing?
EUROIMMUN Medizinische Labordiagnostika AG's recent filing velocity is +307% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for EUROIMMUN Medizinische Labordiagnostika AG's patents?
EUROIMMUN Medizinische Labordiagnostika AG's patents average 10.9 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the EUROIMMUN Medizinische Labordiagnostika AG patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Euroimmun's 71 grants land it in the top 24% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Euroimmun ranks #4,876 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in G01N — see who else leads that technology area. G01N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

G01N technology

EUROIMMUN Medizinische Labordiagnostika AG's primary CPC class — all holders and yearly trends
Top 50 patent holders

See where EUROIMMUN Medizinische Labordiagnostika AG ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov